Home Cart Sign in  
Chemical Structure| 13535-01-8 Chemical Structure| 13535-01-8

Structure of 3-Amino-5-bromopyridine
CAS No.: 13535-01-8

Chemical Structure| 13535-01-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 13535-01-8 ]

CAS No. :13535-01-8
Formula : C5H5BrN2
M.W : 173.01
SMILES Code : NC1=CC(Br)=CN=C1
MDL No. :MFCD01646060
InChI Key :MDQXGHBCDCOOSM-UHFFFAOYSA-N
Pubchem ID :817681

Safety of [ 13535-01-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 13535-01-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 1.0
Molar Refractivity 36.34
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

38.91 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.23
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.86
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.43
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.58
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.41
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.1

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.01
Solubility 1.69 mg/ml ; 0.00978 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.26
Solubility 9.49 mg/ml ; 0.0549 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.51
Solubility 0.531 mg/ml ; 0.00307 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.74 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.54

Application In Synthesis of [ 13535-01-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 13535-01-8 ]

[ 13535-01-8 ] Synthesis Path-Downstream   1~11

  • 1
  • [ 13535-01-8 ]
  • [ 191162-40-0 ]
  • [ 1202550-08-0 ]
YieldReaction ConditionsOperation in experiment
With dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane; potassium phosphate;tris-(dibenzylideneacetone)dipalladium(0); In toluene; at 85℃; for 3h; A flask is charged with 3-amino-5-bromopyridine (0.173 g, 0.950 mmol), Λ/-methyl-indole boronic acid (0.262 g, 1.425 mmol), s-Phos (0.030 g, 0.071 mmol), finely crushed potassium phosphate (0.407 g, 1.900 mmol) and toluene (4 ml_). After degassing for 30 min, Pd2dba3 (0.018 g, 0.019 mmol) is added, the flask is flushed with nitrogen and the mixture is heated to 85 0C. After 3 h, the mixture is allowed to cool to r.t., diluted with ethyl acetate and filtered through a plug of silica gel (elution with ethyl acetate). The <n="133"/>residue is purified by silica gel flash chromatography (heptane-ethyl acetate, 3:7 to 0:1 ) to give 2-(5-amino-pyridin-3-yl)-1-methyl-1 H-indole as an off-white powder. 1H NMR (400 MHz, DMSO-cfe) δ ppm 3.74 (s, 3 H), 5.49 (s, 2 H), 6.56 (s, 1 H), 7.05 - 7.09 (m, 1 H), 7.09 - 7.10 (m, 1 H), 7.17 - 7.21 (m, 1 H), 7.49 (d, J=7.6 Hz, 1 H), 7.57 (d, J=7.6 Hz, 1 H), 7.94 (d, J=2.0 Hz, 1 H), 7.99 (d, J=2.5 Hz, 1 H). MS (ESI) m/z 224 (M+H)+.
  • 2
  • [ 13535-01-8 ]
  • [ 89635-82-5 ]
  • [ 1239131-83-9 ]
  • 3
  • [ 13535-01-8 ]
  • [ 628-36-4 ]
  • [ 1272357-00-2 ]
YieldReaction ConditionsOperation in experiment
33% at 150℃; for 16h; A mixture of 3-bromo-5-amino pyridine (0.30 g, 1.7 mmol) and N,N- diformaylhydrazine (0.15 g, 1.7 mmol) was heated at 150 °C in sealed tube for 16 h. A precipitate formed which was dissolved in hot ethanol and then filtered. Diethyl ether was added to the filtrate at room temperature and the slurry was stirred overnight. The resulting solid was separated and purified by silica gel column chromatography using ethyl acetate and hexanes mixture as the eluent to provide 3- bromo-5-(4H-l,2,4-triazol-4-yl)pyridine (130 mg, 33 percent yield) as a white solid. lH NMR (400 MHz, DMSO-i3/4) delta (ppm): 9.24 (s, 2H); 9.03 (d, 1H, J = 2Hz); 8.79 (d, lH, J = 2Hz); 8.60 (t, lH, J = 2Hz).
  • 4
  • [ 13535-01-8 ]
  • [ 68947-43-3 ]
  • [ 1314734-62-7 ]
YieldReaction ConditionsOperation in experiment
43% Steps 1-2[00200] Oxalyl chloride (8.67 mmol) followed by DMF ( 2drops) was added to a solution of 1 -methyl piperidine-4-carboxylic acid (XLIII) (5.78 mmol) in DCM and stirred 30 min at room temperature under argon. The volatiles were evaporated under vacuum by avoiding contact with air. Pyridine was added to the residue followed by addition of 3-amino-5-bromopyridine (XL) (5.20 mmol). The solution was further stirred at room temperature for 3 h under argon. The pyridine was evaporated under vacuum. The residue was treated with water, basified by saturated NaHC03 solution and washed with DCM. The aqueous layer was extracted with n-butanol. The combined organic layer was evaporated. The residue was dissolved in DCM with the addition of few drops of MeOH. The insoluble inorganic solids were filtered off. The filtrate was concentrated under vacuum to get N-(5-bromopyridin-3-yl)-l-methylpiperidine-4-carboxamide (XLIV) as a brown viscous liquid (0.74 g, 43percent yield). 1H NMR (DMSO-d6) 1.61-1.69 (m, 2H), 1.77-1.79 (m, 2H), 1.93-1.97 (m, 2H), 2.20 (s, 3H), 2.29-2.35 (m, 1H), 2.84- 2.87 (m, 2H), 8.36 (d, J = 1.6 Hz, 1H), 8.39 (m, 1H), 8.66 (d, J = 1.6 Hz, 1H), 10.33 (s, 1H); ESIMS found Ci2Hi6BrN30 mlz 299 (M+H).
  • 5
  • [ 13535-01-8 ]
  • [ 628692-15-9 ]
  • [ 1258620-56-2 ]
YieldReaction ConditionsOperation in experiment
47.5% With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In N,N-dimethyl-formamide; at 120℃;Inert atmosphere; The mixture of 5-bromo-pyriden-3-ylamine (2.6 g, 15 mmol), boronic acid (1.9 g, 12.5 mmol), Pd(PPh3)4 (1.45g, 1.25 mmol), K2C03 (5.18 g, 37.5 mmol) in DMF (50 mL) was stirred at 120°C under N2 overnight. The reaction mixture was concentrated in vacuum. The residue was purified by chromatography on silica gel eluting with EA, to give 1.2 g (yield: 47.5percent) of 5-(2-methoxypyrimidn-5-yl)-3-pyridylamine as yellow solid. [00824] 1H NMR (CDC13, 400 MHz): delta = 8.70 (2H, s), 8.17 (IH, d), 8.13 (IH, d), 7.07 (IH, dd), 4.07 (3H, s).
  • 6
  • [ 13535-01-8 ]
  • [ 628692-15-9 ]
  • [ 1451274-22-8 ]
  • 7
  • [ 13535-01-8 ]
  • [ 1309774-03-5 ]
  • [ 97267-61-3 ]
  • 8
  • [ 13535-01-8 ]
  • [ 1180678-40-3 ]
YieldReaction ConditionsOperation in experiment
42% With N-iodo-succinimide; acetic acid;Reflux; General procedure: NIS (24.75 g, 110.0 mmol) was added to a solution of 2-chloropyridin-4-ylamine (12.85 g, 100.0 mmol) in MeCN (400 mL),and the mixture was stirred and held at reflux overnight. Uponcooling to r.t. the solvent was removed in vacuo and the residuepartitioned between EtOAc (250 mL), sat. Na2S2O3 (100 mL), andH2O (250 mL). The organic layer was separated, washed withH2O (2 × 250 mL), separated, and the solvent removed in vacuoto afford an orange oil that was subjected to column chromatographyon silica gel. Elution with 30-50% EtOAc in PE afforded apale orange solid that was rinsed with 25% EtOAc in PE (80 mL).The solids were collected by filtration and sucked dry to afford2-chloro-5-iodopyridin-4-ylamine (7.32 g) as an off-white solid.The mother liquors were concentrated to dryness in vacuo andthe residues subjected to column chromatography on silica.Elution with 30-50% EtOAc in PE afforded further pure material(1.90 g)
11.5 g With N-iodo-succinimide; acetic acid; at 20℃;Inert atmosphere; 3-Amino-5-bromopyridine (13.8 g, 79.8 mmol) was dissolved in acetic acid (440 mL) and placed under a nitrogen atmosphere. N-lodosuccinimide (16.15 g, 71.8 mmol) was charged to the reaction which was stirred at room temperature overnight. The reaction wasconcentrated and the residue partitioned between EtOAc (200 mL) and saturated aqueous sodium hydrogen carbonate (200 mL). The layers were separated and the organic phase was washed with saturated aqueous sodium hydrogen carbonate (200 mL). The aqueous phase was extracted with EtOAc (3 x 200 mL). The organic extracts were dried over magnesium sulfate, filtered and concentrated. Chromatography (silica; 1.4 Kg packed in70% DCM:30% heptane, eluting with 70-100% DCM in heptane) gave the title compound (11.5 g). 1H NMR (270 MHz, CDCI3): 7.83 (1H, m), 7.04 (1H, m), 4.33 (2H, brs).
11.5 g With N-iodo-succinimide; acetic acid; at 20℃;Inert atmosphere; Preparation 14: 5-Bromo-2-iodo-pyridin-3-ylamine 3-Amino-5-bromopyridine (13.8 g, 79.8 mmol) was dissolved in acetic acid (440 mL) and placed under a nitrogen atmosphere. N-lodosuccinimide (16.15 g, 71.8 mmol) was charged to the reaction which was stirred at room temperature overnight. The reaction was concentrated andthe residue partitioned between EtOAc (200 mL) and saturated aqueous sodium hydrogen carbonate (200 mL). The layers were separated and the organic phase was washed with saturated aqueous sodium hydrogen carbonate (200 mL). The aqueous phase was extracted with EtOAc (3 x 200 mL). The organic extracts were dried over magnesium sulfate, filtered and concentrated. Chromatography (silica; 1.4 Kg packed in 70% DCM:30% heptane, eluting with70-100% DCM in heptane) gave the title compound (11.5 g). 1H NMR (270 MHz, CDCI3): 7.83 (1H, m), 7.04 (1H, m), 4.33 (2H, brs).
11.5 g With N-iodo-succinimide; acetic acid; at 20℃;Inert atmosphere; Preparation II: 5-Bromo-2-iodo-pyridin-3-ylamine H2N3-Amino-5-bromopyridine (13.8 g, 79.8 mmol) was dissolved in acetic acid (440 mL) and placed under a nitrogen atmosphere. N-lodosuccinimide (16.15 g, 71.8 mmol) was charged to the reaction which was stirred at room temperature overnight. The reaction wasconcentrated and the residue partitioned between EtOAc (200 mL) and saturated aqueous sodium hydrogen carbonate (200 mL). The layers were separated and the organic phase was washed with saturated aqueous sodium hydrogen carbonate (200 mL). The aqueous phase was extracted with EtOAc (3 x 200 mL). The organic extracts were dried over magnesium sulfate, filtered and concentrated. Chromatography (silica; 1.4 Kg packed in70% DCM:30% heptane, eluting with 70-100% DCM in heptane) gave the title compound (11.5g). 1H NMR(27OMHz, CDCI3): 7.83(1H, m), 7.04(1H, m),4.33(2H, brs).

  • 9
  • [ 13535-01-8 ]
  • [ 1309774-03-5 ]
  • 10
  • [ 13535-01-8 ]
  • [ 1201645-46-6 ]
  • 11
  • [ 13535-01-8 ]
  • [ 72040-64-3 ]
  • N-(4-((5-bromopyridin-3-yl)amino)-4-oxobutyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
55.4% Thionyl chloride (20equiv) was added dropwise to dry solid 7 (1equiv) at 0°C. The solution was stirred overnight at room temperature. The thionyl chloride in excess was removed under reduced pressure. Then the product was dissolved in DCM and added dropwise to 3-amino-5-bromopyridine (1equiv) in DCM at 0°C. The resulting mixture was stirred overnight at room temperature. The product was filtered, washed with saturated solution of NaHCO3, and dried under vacuum.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 13535-01-8 ]

Bromides

Chemical Structure| 239137-39-4

A113373 [239137-39-4]

3-Amino-4-bromopyridine

Similarity: 0.86

Chemical Structure| 90902-84-4

A178478 [90902-84-4]

2,5-Dibromopyridin-3-amine

Similarity: 0.85

Chemical Structure| 850892-12-5

A154944 [850892-12-5]

5-Bromo-4-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 914358-73-9

A180667 [914358-73-9]

5-Bromo-2-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 4635-08-9

A393690 [4635-08-9]

5-Bromopyridine-3,4-diamine

Similarity: 0.82

Amines

Chemical Structure| 239137-39-4

A113373 [239137-39-4]

3-Amino-4-bromopyridine

Similarity: 0.86

Chemical Structure| 90902-84-4

A178478 [90902-84-4]

2,5-Dibromopyridin-3-amine

Similarity: 0.85

Chemical Structure| 850892-12-5

A154944 [850892-12-5]

5-Bromo-4-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 914358-73-9

A180667 [914358-73-9]

5-Bromo-2-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 4635-08-9

A393690 [4635-08-9]

5-Bromopyridine-3,4-diamine

Similarity: 0.82

Related Parent Nucleus of
[ 13535-01-8 ]

Pyridines

Chemical Structure| 239137-39-4

A113373 [239137-39-4]

3-Amino-4-bromopyridine

Similarity: 0.86

Chemical Structure| 90902-84-4

A178478 [90902-84-4]

2,5-Dibromopyridin-3-amine

Similarity: 0.85

Chemical Structure| 850892-12-5

A154944 [850892-12-5]

5-Bromo-4-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 914358-73-9

A180667 [914358-73-9]

5-Bromo-2-methylpyridin-3-amine

Similarity: 0.83

Chemical Structure| 4635-08-9

A393690 [4635-08-9]

5-Bromopyridine-3,4-diamine

Similarity: 0.82